News & Updates

More treatment modifications secondary to adverse events appear necessary among obese patients receiving ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate indicated for the treatment of HER2-positive breast cancer, relative to nonobese counterparts, reports a study.

Women appear to be at higher risk of colorectal cancer death following adenoma removal, whereas men are at lower risk, as reported in a recent study.

An exercise and dietary lifestyle intervention regimen leads to better mobility outcomes among prostate cancer patients undergoing androgen deprivation therapy (ADT) as compared with standard-of-care management, a recent study has found. Moreover, social cognitive outcome measures seem to be predictive of such mobility outcomes.

The use of unopposed oestrogen in menopausal women may contribute to a heightened risk of cutaneous melanoma, a study has found.

The anti-CD19 chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel did not improve event-free survival (EFS) compared with standard care in patients refractory or who had progressed following first-line therapy for aggressive B-cell non-Hodgkin’s lymphoma, results of the phase III BELINDA trial showed.

The risk stratification criteria used in the CHAARTED and LATITUDE trials can accurately assess prognosis in patients with castration-resistant prostate cancer (CRPC), but are insufficient to differentiate between the therapeutic outcomes of androgen receptor pathway inhibitors (ARPI) and docetaxel, a new study has found.

Levels of prostate specific antigen (PSA) mRNA in circulating tumour cells can be used alongside serum PSA protein levels to refine the assessment of disease progression in patient with metastatic castration-resistant prostate cancer (mCRPC), a new study has found.